Lifecore Biomedical, Inc. \De\ (LFCR) Preferred Stock Liabilities (2023 - 2025)
Lifecore Biomedical, Inc. \De\ (LFCR) posted quarterly Preferred Stock Liabilities of $46.1 million for Q2 2025, up 8.24% year-over-year from $42.6 million in Q2 2024, and up 1.99% quarter-over-quarter from $45.2 million in Q1 2025.
Lifecore Biomedical, Inc. \De\ (LFCR) Preferred Stock Liabilities (2023 - 2025) Analysis & Trends
Lifecore Biomedical, Inc. \De\'s Preferred Stock Liabilities history runs 3 years deep, the most recent figure standing at $46.1 million for Q2 2025.
- In Q2 2025, Preferred Stock Liabilities rose 8.24% year-over-year to $46.1 million; the TTM figure through May 2025 stood at $46.1 million (up 8.24% YoY), while the FY2025 annual figure was $46.1 million, up 8.24% from the prior year.
- Preferred Stock Liabilities for Q2 2025 stood at $46.1 million, up from $45.2 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $46.1 million in Q2 2025, with the low at $38.5 million in Q1 2023.
- The 3-year median for Preferred Stock Liabilities is $42.2 million (2024), against an average of $42.2 million.
- The sharpest annual moves came in 2024 and 2025: Preferred Stock Liabilities rose 8.34% in 2024, then advanced 8.24% in 2025.
- Lifecore Biomedical, Inc. \De\'s Preferred Stock Liabilities stood at $40.9 million in 2023, then gained by 8.28% to $44.3 million in 2024, then advanced by 4.03% to $46.1 million in 2025.
- Business Quant data shows LFCR's Preferred Stock Liabilities at $46.1 million in Q2 2025, $45.2 million in Q1 2025, and $44.3 million in Q4 2024.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| May 25, 2025 | 46.10 Mn |
| Feb 23, 2025 | 45.20 Mn |
| Nov 24, 2024 | 44.31 Mn |
| Aug 25, 2024 | 43.44 Mn |
| May 26, 2024 | 42.59 Mn |
| Feb 25, 2024 | 41.75 Mn |
| Nov 26, 2023 | 40.92 Mn |
| Aug 27, 2023 | 40.11 Mn |
| May 28, 2023 | 39.32 Mn |
| Feb 26, 2023 | 38.54 Mn |